# TherapeuticsMD, Inc.: Form 10-Q for the period ended Mar 31, 2012

- Company: [TherapeuticsMD, Inc.](/companies/txmd.md) (CIK 25743)
- Form: 10-Q
- Filed: 2012-05-11
- Accepted by EDGAR: May 11, 2012, 16:58 ET
- Period: 2012-03-31
- Accession: 0001387131-12-001510
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/25743/000138713112001510/txmd-10q_033112.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/25743/000138713112001510/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-01-01 to 2012-03-31 | $721.7k | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2012-01-01 to 2012-03-31 | $336.1k | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2012-01-01 to 2012-03-31 | $385.6k | us-gaap:GrossProfit |
| Research and development | 3 months, 2012-01-01 to 2012-03-31 | $412.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2012-01-01 to 2012-03-31 | $2.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2012-01-01 to 2012-03-31 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-01-01 to 2012-03-31 | $102.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2012-01-01 to 2012-03-31 | −$13.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2012-01-01 to 2012-03-31 | −$0.16 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2012-01-01 to 2012-03-31 | −$2.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2012-01-01 to 2012-03-31 | $32.4k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2012-03-31 | $195.2k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-03-31 | $1.3m | us-gaap:AssetsCurrent |
| Total assets | at 2012-03-31 | $1.5m | us-gaap:Assets |
| Current liabilities | at 2012-03-31 | $2.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-03-31 | $4.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2012-03-31 | −$3.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 14,636 characters.

### General

The following discussion and analysis provides information which management of the Company believes to be relevant to an assessment and understanding of the Company’s results of operations and financial condition. This discussion should be read together with the Company’s condensed consolidated financial statements and the notes to the financial statements, which are included in this report. This information should also be read in conjunction with the information contained in our Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 27, 2012, including the audited financial statements and notes included therein. The reported results will not necessarily reflect future results of operations or financial condition.

Throughout this Quarterly Report on Form 10-Q (the “Report”), the terms “we,” “us,” “our,” “Therapeutics,” or “our Company” refers to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, includes its wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company (“VitaMed”) and BocagreenMD, Inc., a Nevada corporation (“Bocagreen”), incorporated on January 10, 2012.

### Overview

VitaMed is a specialty pharmaceutical company organized as a limited liability company in the State of Delaware on May 13, 2008. VitaMed is focused on providing the highest quality products to the women’s health market. Our national sales force that calls on physicians and pharmacies is enhanced by our patent-pending technology and business methodology. This combination allows us to market both over-the-counter (“OTC”) and prescription nutritional supplements, drugs, medical foods and other medical products through pharmacies and our web-site with the recommendation of physicians by creating a unique value proposition for patients, physician/providers and insurance payors.

The Company’s Common Stock is traded on the OTCQB under the symbol “TXMD.” The Company maintains a website at www.therapeuticsmd.com and VitaMed maintains websites at www.vitamedmd.com and www.vitamedmdrx.com.

#### Approval of 2012 Stock Incentive Plan

On February 23, 2012, the Company’s Board of Directors adopted the 2012 Stock Incentive Plan, a non-qualified plan not requiring approval by the Company’s shareholders (“2012 SOP”). The 2012 SOP was designed to serve as an incentive for retaining qualified and competent key employees, officers and directors, and certain consultants and advisors of the Company. There are 10,000,000 shares authorized for issuance thereunder. No shares have been issued under the 2012 SOP.

#### Issuance of Secured Promissory Notes

On February 24, 2012, the Company issued secured promissory notes (the “Notes”) to an individual and an entity (the “Parties”) in the principal base amount of $1,358,014 and $1,357,110 respectively and granted warrants for the purchase of the Company’s Common Stock (“Warrants”) in the aggregate of 9,000,000 shares (the “February 2012 Warrants”) (for more details, see *Issuance of Warrants* below) pursuant to the terms of a Note Purchase Agreement also dated February 24, 2012. As consideration for the Notes and the February 2012 Warrants, the Company received an aggregate of $1,000,000 of new funding from the Parties and the Parties surrendered certain promissory notes previously issued by the Company in the aggregate amount of $858,014 and $857,110 respectively. See NOTE H – NOTES PAYABLE in the accompanying financial statements for more details.

#### Change in Officers and Directors

On February 29, 2012, the Company’s Board of Directors elected four additional individuals to serve as members of its Board of Directors, namely: Samuel A. Greco, Cooper C. Collins, Robert V. LaPenta, Jr. and Nicholas Segal.

#### Approval of Committee Charters and Committee Appointments

On February 29, 2012, the Company’s Board of Directors (i) approved charters for each of the Audit Committee, Compensation Committee and Corporate Governance Committee, (ii) appointed members to each committee and (iii) named a Chair of each committee.

- Members elected to the Audit Committee include Robert V. LaPenta, Jr., Samuel A. Greco and Nicholas Segal. Mr. LaPenta, Jr. will serve as Chair.
- Members elected to the Compensation Committee include Cooper C. Collins, Robert G. Finizio and Nicholas Segal. Mr. Collins will serve as Chair.
- Members elected to the Corporate Governance Committee include John Milligan, Brian Bernick and Robert V. LaPenta, Jr. Mr. Milligan will serve as Chair.

#### New Products

On March 1, 2012, the Company launched its first prescription prenatal vitamin, *vitaMedMD™ Plus Rx. vitaMedMD Plus Rx* is a single-dose product containing one prenatal vitamin tablet and one life’s DHA capsule.

On April 9, 2012, the Company launched its second prescription prenatal vitamin, *vitaMedMD™ Plus One. vitaMedMD Plus One* is a single dose containing one softgel with 14 vitamins, minerals and 200 mg of plant-based DHA.

On May 10, 2012, the Company launched its third prescription prenatal vitamin, *vitaMedMD™ RediChew™ Rx. vitaMedMD RediChew Rx* is a small, vanilla flavored, chewable prenatal vitamin tablet that dissolves quickly and is taken once daily.

### Results of Operations

The following information presents the results of operations for the Company’s continuing operations for the three month periods ended March 31, 2012 and 2011. The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements included herewith and our Annual Report on Form 10-K filed with the SEC on March 27, 2012. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management. Historical financial information presented for the three months ended March 31, 2012 and 2011 is that of the Company on a consolidated basis with its subsidiaries.

#### Three months ended March 31, 2012 compared to three months ended March 31, 2011

|  | Three Months Ended March 31, 2012 | 2011 (000’s) | Change |
| --- | ---: | ---: | ---: |
| Revenue | $722 | $486 | $236 |
| Cost of goods sold | 336 | 204 | 132 |
| Operating expenses | 3,254 | 1,053 | 2,201 |
| Operating loss | (2,868) | (771) | (2,097) |
| Loss on extinguishment of debt | (10,308) | -0- | (10,308) |
| Other expense, net | (114) | (3) | (111) |
| Net loss | $(13,290) | $(774) | $(12,516) |

#### Revenue and Cost of Goods Sold

Revenues for three months ended March 31, 2012 were up $236,000, or approximately 49%, from the three months ended March 31, 2011. This increase was directly attributable to the (i) increase in the number of sales territories, (ii) the associated increase in number of sales people selling in those territories and (iii) the new prescription product introduced in March 2012. Cost of Goods Sold increased $132,000, or approximately 65%, for the three months ended March 31, 2012 compared to the three months ended March 31, 2011. Approximately 87% of this increase was due to an increase in the amount of product sold and approximately 13% of the increase was related to product mix. The Company’s costs of individual products did not change for the three months ended March 31, 2012 as compared to the same period in 2011.

#### Operating Expenses

The Company’s principal operating costs include the following items as a percentage of total expense.

|  | Three Months Ended March 31, 2012 | 2011 |
| --- | ---: | ---: |
| Human resource costs, including commission and benefits | 44.0% | 55.6% |
| Product design and development costs | 12.7% | 5.2% |
| Sales and marketing, excluding human resources and travel and entertainment | 10.7% | 10.7% |
| Professional fees for legal, accounting and consulting | 9.6% | 2.1% |
| Travel and entertainment costs | 8.2% | 6.5% |
| Non-cash costs | 4.4% | 5.0% |
| Other | 10.4% | 14.9% |

Operating expenses increased by $2.2 million (209%) as a result of the following items:

|  | (000’s) |
| --- | ---: |
| Increase in human resource costs | $845 |
| Increase in product design and development costs | 357 |
| Increase in professional, accounting and consulting | 292 |
| Increase in sales and marketing | 234 |
| Increase in travel and entertainment | 197 |
| Increase in non-cash costs | 92 |
| Increase in all other | 184 |
|  | $2,201 |

20

Human resource related costs (including salaries, commission, and benefits) was higher as a result of an increase of 37 employees between the two periods (approximately $659,000) and increased sales commissions of approximately $186,000.

Product design and development costs increased as a direct result of our new prescription prenatal products.

Professional fees increased primarily due to a higher legal fees arising from contract and patent services and public company filing related costs (approximately $179,000). The Company experienced higher accounting and audit costs related to preparation of audits and public company filing related costs (approximately $86,000). Consulting costs were also higher as a result of opening new sales territories and the additional resources needed for public company filings (approximately $27,000).

Sales and marketing costs increased due to the addition of new sales territories and expanded client education.

Travel and entertainment expense increased as a direct result of increased activity associated with sales and training efforts.

Non-cash costs were higher as the result of the Warrants issued for services (approximate fair value of $56,000) and additional Options related costs (approximate fair value of $36,000).

#### Loss on extinguishment of debt

In February 2012 (as described above), the Company issued Notes in the aggregate of approximately $2,700,000 and granted Warrants for the purchase of an aggregate of 9,000,000 shares. As consideration for the Notes and the Warrants, the Company received of $1,000,000 of new funding and the surrender of certain promissory notes previously issued by the Company in the aggregate amount of approximately $1,700,000 (the "Prior Notes"). The Company determined that the resulting modification of the Notes was substantial in accordance with ASC 470-50, “*Modifications and Extinguishments.”* As such the modification was accounted for as an extinguishment and restructuring of the debt, and the Warrants issued, valued at approximately $10,500,000, were expensed as loss on the extinguishment of debt. The relative fair value of the Prior Notes was estimated to be $1,500,000 by calculating the present value of future cash flows discounted at a market rate of return for comparable debt instruments. The Company recognized a reduction in loss on extinguishment of debt in the amount of $200,000, which represented the difference between the net carrying amount of the New Funding and its fair value. See NOTE I – STOCKHOLDERS’ EQUITY, Warrants and NOTE H – NOTES PAYABLE in the accompanying financial statements for more details.

#### Other Expense, net

Other non-operating expense increased by approximately $111,000 for the three months ended March 31, 2012 in comparison to the same period in 2011 due primarily to the addition of interest expense not incurred during 2011.

### Liquidity and Capital Resources

As of March 31, 2012, the Company’s working capital deficit was approximately $1,300,000, our accumulated deficit was approximately $30,300,000 and our stockholders’ deficit was approximately $3,400,000.

We began the operation of our current business plan in June 2008 and have not yet attained a level of revenue to allow us to meet our current overhead. Based on our current marketing plan and expected sales demand, we do not contemplate attaining profitable operations until 2013, and there is no assurance that such an operating level can ever be achieved. We are dependent upon obtaining additional financing in order to adequately fund working capital, infrastructure, manufacturing expenses and significant marketing/investor related expenditures to gain market recognition, so that we can achieve a level of revenue adequate to support our cost structure, none of which can be assured. Management believes it will be able to raise the capital required to execute the Company’s business plan and become profitable.

While we believe that we will have sufficient financial resources for the next twelve (12) month period, we cannot provide assurance as to how much we will need to spend in order to develop, manufacture, and market new products and technologies in the future. We are currently working to bring additional products to market including prescription products for the treatment of menopausal symptoms for which clinical studies will be conducted and for which FDA approval will be sought. We expect to spend at least $3,000,000 on research and development in 2012, which amount could increase based on positive research results and funding. As we increase the market penetration of our current products and we expand our product base to include prescription products, the need for increased inventory levels will become a necessity. This increase is estimated to be approximately $800,000.

We may not have sufficient resources to fully develop any new products or technologies or expand our inventory levels unless we are able to raise additional financing. We can make no assurances these required funds will be available on favorable terms, if at all. If additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in dilution to our existing stockholders. Additionally, these conditions may increase costs to raise capital and/or result in further dilution. Our failure to raise capital when needed would adversely affect our business, financial condition and results of operations, and could force us to reduce or cease our operations.

We believe that we will be able to meet the costs of growth and public reporting with funds generated from operations and additional amounts generated through debt and equity financing. Although management believes that the required financing to fund product development and increasing inventory levels can be secured at terms satisfactory to the Company, there is no guarantee these funds will be made available, and if funds are available, that the terms will be satisfactory to the Company.

### Off-Balance Sheet Arrangements

None.

## Market risk

As filed, 170 characters.

Our Company is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and as such, is not required to provide the information required under this item.

## Controls and procedures

As filed, 1,985 characters.

#### Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms and is accumulated and communicated to Robert G. Finizio, the Company’s Chief Executive Officer, as appropriate, in order to allow timely decisions in connection with required disclosure.

#### Evaluation of Disclosure Controls and Procedures

Robert G. Finizio and Daniel A. Cartwright, currently serving as the Company’s Chief Executive Officer and Chief Financial Officer respectively, evaluated the effectiveness of the design and operation of our Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15 and 15d-15 under the Exchange Act) as of the end of the period covered by this quarterly report. Based on such evaluation, they concluded that the Company’s disclosure controls and procedures are not effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in SEC’s rules and forms. During the most recently completed three-month period ended March 31, 2012, there has been no significant change in the Company’s internal control over financial reporting that has affected, or is reasonably likely to affect, the Company’s internal control over financial reporting.

#### Changes in Internal Controls

During the three months ended March 31, 2012, there were no significant changes in internal controls of the Company, or other factors that could significantly affect these controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Filed May 11, 2012.
Source: SEC EDGAR, the filing index for accession 0001387131-12-001510. Last ingested by Listed: Nov 14, 2026, 19:24 ET. No prices; not investment advice.
